All the news Showing 4 of 44 articles from: Genotype 3Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir + ribavirin cures most genotype 2 hepatitis C, but genotype 3 response is lower Liz Highleyman / 26 April 2013 A dual oral regimen containing the hepatitis C nucleotide polymerase inhibitor sofosbuvir plus ribavirin produced high sustained virological rates overall, but this was driven by very good response amongst people with HCV genotype ... Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C Gilead press release / 09 April 2013 Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients Gilead press release / 27 November 2012 Sofosbuvir and daclatasvir dual regimen cures most people with HCV genotypes 1, 2, or 3 Liz Highleyman / 21 November 2012 A 12-week, once-daily regimen of the hepatitis C (HCV) polymerase inhibitor sofosbuvir and the NS5A inhibitor daclatasvir, without interferon or ribavirin, produced sustained virological response rates for treatment-naive people in the 90 to 100% range, ... ← Prev12345Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive